報價延遲最少15分鐘:2025/06/02 15:19 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.905 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.36/-4.52
|
|
企業價值
252.74M
|
| 資產負債 |
|
每股賬面淨值
20.46
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
925.00K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/02 15:19 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid. |